C10orf31 Inhibitors
The specific inhibitors targeting the activity of C10orf31 indirectly influence the protein's function by modulating the cellular pathways it may be involved in. Kinase inhibitors, such as those affecting broad-spectrum protein kinase activity, can diminish C10orf31's action if its function is regulated via phosphorylation events. This approach is relevant particularly if C10orf31 operates within the signaling cascades that are controlled by kinase-mediated activation or deactivation. Similarly, inhibitors that specifically target the PI3K/mTOR pathway would be effective if C10orf31 resides within this signaling axis, as the inhibition of PI3K or mTOR would prevent the downstream activation of C10orf31.
In addition, inhibitors of the MAPK pathway, including those of MEK and p38 MAPK, offer a targeted approach to suppressingInhibitors that target specific biochemical pathways can provide indirect but effective means of inhibiting the activity of C10orf31, assuming it is a protein whose functional activity is contingent on certain signaling cascades or post-translational modifications. Compounds that inhibit kinase activity, for instance, could lead to a reduction in the functional activity of C10orf31 if its role is subject to regulation by phosphorylation. By preventing the addition or removal of phosphate groups, these inhibitors could effectively reduce the activity of C10orf31. This is particularly applicable if C10orf31 is an integral part of pathways controlled by kinase signaling, where phosphorylation acts as a molecular on-off switch, determining the protein's functional state. For example, if C10orf31 activity is dependent on PI3K pathway signals or if it operates downstream of mTOR, specific inhibitors of these pathways would impede the activation of C10orf31 by blocking necessary upstream signals.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent non-selective inhibitor of protein kinases. By broadly inhibiting kinase activity, staurosporine can indirectly lead to the inhibition of C10orf31 if its function is regulated by phosphorylation, thereby reducing its activity by preventing its activation or degradation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K. Given C10orf31 activity is dependent on signals downstream of the PI3K pathway, LY294002 will inhibit this pathway, likely reducing the functional activity of C10orf31 by preventing its activation through this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor. If C10orf31 functions downstream of mTOR signaling, rapamycin inhibition of mTOR could result in decreased activity of C10orf31 by preventing its activation or expression that is mTOR-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. Inhibition of MEK, and thus ERK, could lead to decreased activity of C10orf31 given it is regulated by the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK. Given C10orf31 is activated by p38 MAPK signaling, then inhibition by SB203580 would prevent its activation, leading to a decrease in C10orf31 functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
An inhibitor of PI3K like LY294002. Given C10orf31 is PI3K pathway-dependent, wortmannin would inhibit this pathway, reducing the activity of C10orf31. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK pathway. Given C10orf31 is regulated by JNK signaling, SP600125 would inhibit this pathway and thus might reduce the functional activity of C10orf31. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
A selective inhibitor of Aurora kinases. Given C10orf31 is involved in cell cycle regulation or other processes controlled by Aurora kinases, inhibition by ZM-447439 could decrease the activity of C10orf31. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor. Given the function of C10orf31 involves degradation of specific proteins, inhibition of the proteasome by bortezomib could lead to altered levels of these proteins and thus indirectly inhibit the function of C10orf31. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
A receptor tyrosine kinase inhibitor. Given C10orf31 activity is modulated by receptor tyrosine kinases, sunitinib could decrease its activity by inhibiting the kinases that activate it. | ||||||